|
Basic Characteristics of Mutations
|
|
Mutation Site
|
T97A |
|
Mutation Site Sentence
|
Table 2.Human Immunodeficiency Virus Type 1 Genotype at Screening/Baseline |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
nonsynonymous substitution |
|
Gene/Protein/Region
|
IN |
|
Standardized Encoding Gene
|
gag-pol:155348
|
|
Genotype/Subtype
|
HIV-1 |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
HIV Infections
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
Y |
|
Treatment
|
integrase inhibitor |
|
Location
|
United States |
|
Literature Information
|
|
PMID
|
31879782
|
|
Title
|
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study
|
|
Author
|
Huhn GD,Crofoot G,Ramgopal M,Gathe J,Bolan R,Luo D,Simonson RB,Nettles RE,Benson C,Dunn K
|
|
Journal
|
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
|
|
Journal Info
|
2020 Dec 15;71(12):3110-3117
|
|
Abstract
|
BACKGROUND: Most guidelines recommend rapid treatment initiation for patients with newly diagnosed human immunodeficiency virus type 1 (HIV-1) infection, but prospective US data are limited. The DIAMOND (NCT03227861) study using darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is a phase 3 prospective study evaluating efficacy/safety of a single-tablet regimen in a rapid-initiation model of care. METHODS: Adults aged >/=18 years began D/C/F/TAF =14 days from diagnosis without screening/baseline results; as results became available, participants not meeting predefined safety/resistance stopping rules continued. Primary endpoint was virologic response (HIV-1 RNA <50 copies/mL; intent-to-treat; US Food and Drug Administration [FDA] snapshot) at week 48; participant satisfaction was measured via the HIV Treatment Satisfaction Questionnaire status version (HIVTSQs). RESULTS: Of 109 participants, 87% were male, 32% black/African American, median (range) age was 28 (range, 19-66) years, 25% of participants had HIV-1 RNA >/=100 000 copies/mL, 21% had CD4+ cell count <200 cells/microL, and 31% enrolled =48 hours from diagnosis. At week 48, 97 (89%) participants completed the study and 92 (84%) achieved HIV-1 RNA <50 copies/mL (FDA snapshot). There were no protocol-defined virologic failures; incidences of adverse events (AEs) and adverse drug reactions (33%) were low, no serious AEs were study drug related, and 1 (<1%) participant discontinued due to study drug related AE(s). The overall HIVTSQs score at week 48 was 58 (maximum: 60). CONCLUSIONS: At week 48, a high proportion of participants starting D/C/F/TAF achieved HIV-1 RNA <50 copies/mL and very few discontinued therapy. D/C/F/TAF was well tolerated, no participants discontinued due to baseline resistance stopping criteria, and high treatment satisfaction among participants was recorded. CLINICAL TRIALS REGISTRATION: NCT03227861.
|
|
Sequence Data
|
-
|
|
|